BBR 2778

· CTI BioPharma

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BBR 2778, covering 2017-06-01 to 2017-06-01. Get the full timeline:

Most recent: Clinical Trial Update: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 3]